Home › Esophageal Adenocarcinoma › Delaware › Newark
Esophageal Adenocarcinoma clinical trials in Newark, DE
3 studies for Esophageal Adenocarcinoma are looking for participants at sites in and around Newark (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
RecruitingPhase 2/3
- Helen F Graham Cancer Center, Newark
- Medical Oncology Hematology Consultants PA, Newark
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
RecruitingPhase 3
- Helen F Graham Cancer Center, Newark
- Medical Oncology Hematology Consultants PA, Newark
- Christiana Care Health System-Christiana Hospital, Newark
- and 1 more
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
RecruitingPhase 3
- Research Site, Newark
Esophageal Adenocarcinoma trials in other cities
- New York City, NY18 studies
- Boston, MA13 studies
- Houston, TX12 studies
- Nashville, TN11 studies
- Arlington, VA11 studies
- Durham, NC10 studies
- Jacksonville, FL9 studies
- Baldwin Park, CA9 studies
- Rochester, MN9 studies
- St. Louis, MO9 studies
- Queens, NY9 studies
- Los Angeles, CA9 studies
Other studies in Newark
- Non-Small Cell Lung Cancer16 studies
- Prostate Cancer10 studies
- Lung Cancer9 studies
- Colorectal Cancer9 studies
- Breast Cancer8 studies
- Metastatic Cancer7 studies
- Pancreatic Cancer6 studies
- Cancer (all types)6 studies
- Ovarian Cancer5 studies
- Stomach Cancer4 studies
- Bladder Cancer4 studies
- Melanoma4 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.